KRAS mutations increase the glucose uptake in CRC cells via the upregulation of GLUT1 to generate more glycolytic intermediates for the utilization in different metabolic pathways in tumor expansion (Kawada et al., 2012; Iwamoto et al., 2014). Here, KRAS is linked to colorectal carcinoma.